Published: Wed, January 31, 2018
Sci-tech | By Brandy Patterson

Influential Analyst Rating Changes: Editas Medicine, Inc. (EDIT), Protagonist Therapeutics, Inc. (PTGX)

Editas Medicine (NASDAQ:EDIT) was upgraded by equities research analysts at BidaskClub from a "buy" rating to a "strong-buy" rating in a research report issued to clients and investors on Tuesday.

On Wednesday, November 1st, Katrine Bosley sold 8,333 shares of Editas Medicine stock.

More news: Reduces Position in Valley National Bancorp (VLY)

CFO, Hack Andrew A. F., sold 14,649 common shares of Editas Medicine, Inc. Similar to the other ratios, a lower number might raise red flags about management's ability when compared to other companies in a similar sector. There were 16 sold out positions, amounting to 1.34 million shares. Cowen reiterated a "buy" rating on shares of Editas Medicine in a report on Tuesday, November 7th. ValuEngine lowered Editas Medicine from a "hold" rating to a "sell" rating in a research report on Friday, December 1st.

Institutions own 64.10% of Editas Medicine, Inc. Finally, SunTrust Banks, Inc. started coverage on shares of Editas Medicine in a report on Thursday, July 13th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Editas Medicine now has an average rating of "Buy" and an average price target of $30.73. (NASDAQ:CYTX) has been 1.4 million shares per day over the past 30 days. The firm has a market capitalization of $1,590.00 and a PE ratio of -11.10. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. Microsemi Corporation has 52-Week high of $65.65 and 52-Week Low of $46.09. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.60) by ($0.04). Recently, analysts have updated the overall rating to 2.38. The Return on Assets for Editas Medicine, Inc. Careful investors will no doubt be combing through specific company data to make sure the fundamentals are in line as well. (NASDAQ:EDIT) was released by: and their article: "Editas Medicine Reaches Analyst Target Price" with publication date: January 03, 2018. And the values below 20 that it is oversold indicate prices could very well bounce upwards. Institutional owners hold 79.70% stake while Insiders ownership held at 3.00% in the company. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

More news: Nigeria Enters Single Aviation Market Agreement With 22 African Countries

In other Editas Medicine news, insider Gerald Frank Cox acquired 4,000 shares of the firm's stock in a transaction that occurred on Friday, June 2nd. The stock was sold at an average price of $23.64, for a total value of $196,992.12. Companies may issue new shares and buy back their own shares. The disclosure for this sale can be found here. The stock traded with the volume of 3 Million shares yesterday. (EDIT) snatched the consideration from Investors, when its current beneficial picture was seen that is promoting good health. Editas Medicine earned a coverage optimism score of 0.07 on Accern's scale. Great West Life Assurance Co. The company's quarterly revenue was up 553.0% compared to the same quarter a year ago.

The top 5 institutional holders, in ascending order, are as follows: FMR LLC with 4.53 million shares, BLACKROCK INC. with 2.64 million shares, VANGUARD GROUP INC with 2.3 million shares, STATE STREET CORP with 1.85 million shares, and POLARIS VENTURE MANAGEMENT CO. The quarterly performance is giving indications that stock is trading with a tendency toward upward trend. Finally, Plancorp LLC acquired a new position in Editas Medicine in the fourth quarter worth approximately $235,000. The Shareholder Yield of Editas Medicine, Inc. If you are accessing this story on another publication, it was copied illegally and reposted in violation of worldwide copyright laws. Editas Medicine Cmn (NASDAQ:EDIT) has trailing twelve month Return on Assets of -37.1%, which is key indicator of how profitable a company is relative to its total assets. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. It operates through developing and commercializing genome editing technology segment.

More news: Healthcare Realty Trust (NYSE:HR) Given Daily Coverage Optimism Rating of 0.30

Like this: